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Abstract
Congenital Cataracts Facial Dysmorphism Neuropathy (CCFDN) syndrome is a complex
developmental disorder of autosomal recessive inheritance. To date, CCFDN has been found to
occur exclusively in patients of Roma (Gypsy) ethnicity; over 100 patients have been diagnosed.
Developmental abnormalities include congenital cataracts and microcorneae, primary
hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor
and intellectual development, mild facial dysmorphism and hypogonadism. Para-infectious
rhabdomyolysis is a serious complication reported in an increasing number of patients. During
general anaesthesia, patients with CCFDN require careful monitoring as they have an elevated risk
of complications. CCFDN is a genetically homogeneous condition in which all patients are
homozygous for the same ancestral mutation in the CTDP1 gene. Diagnosis is clinical and is
supported by electrophysiological and brain imaging studies. The major differential diagnosis is
Marinesco-Sjögren syndrome. The definitive diagnosis is molecular, based on homozygosity for the
CTDP1 mutation. CTDP1 maps to 18qter and encodes a protein phosphatase whose only known
substrate is the phosphorylated serine residues of the carboxy-terminal domain of the largest
subunit of RNA polymerase II, indicating that CCFDN affects basic cellular processes of gene
expression and developmental regulation. Families benefit from genetic counselling and predictive
testing. Management includes surgical treatment of the cataracts, and rehabilitation and corrective
orthopaedic surgery for the peripheral neuropathy. Thus, the most disabling manifestations, though
not curable, are manageable, and allow an acceptable quality of life and everyday living. Current data
indicate that patients survive well into adulthood.
Disease name
Congenital Cataracts Facial Dysmorphism Neuropathy
(CCFDN) syndrome
Definition/diagnostic criteria
CCFDN is a complex developmental disorder of auto-
somal recessive inheritance which, so far, has been found
to occur exclusively in patients of Roma (Gypsy) ethnicity
[1,2].
Primary diagnostic criteria
• Bilateral congenital cataracts, microcornea, microph-
thalmos, micropupils
• Developmental delay
• Small stature and low weight
• Hypo/demyelinating neuropathy
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• Mild hypogonadism
Additional criteria
• Mild cognitive deficit




The CCFDN mutation is particularly common among the
Rudari, an endogamous, recently founded Roma popula-
tion, in whom the carrier rate is around 6–7% [3,4]. In
other Gypsy groups, it is ~1%. The disorder has so far been
diagnosed in over 100 Roma patients, whose countries of
residence reflect past and recent migrations of the affected
population, as well as access to healthcare and awareness
of this syndrome among health care providers. Most
known affected subjects belong to the traditional Roma
population of Balkan and Central European countries
(Bulgaria, Romania, Serbia, Greece, Hungary, the Czech
Republic), or are recent migrants to Austria and Germany;
with cases also diagnosed in Italy, France, The Nether-
lands, USA and Canada. CCFDN should be considered as
the most likely diagnosis in infants of Roma ethnicity pre-
senting with congenital cataracts.
Clinical description
The CCFDN phenotype is complex and affects multiple
organs and tissues, mostly during intra-uterine develop-
ment. Detailed descriptions of the clinical manifestations
are available [2,5-7].
Prenatal eye development is invariably affected and the
congenital cataracts are the first CCFDN manifestation,
recognisable in early infancy. The cataracts are bilateral
and are characterised by anterior or posterior cortical
dense opacities with clouding of the adjacent part of the
lens nucleus or total cataracts involving the whole lens.
These are accompanied by microcornea, microphthalmos
and micropupils. Additional ophthalmological features
include floppy eyelids and long and dense eyelashes, nys-
tagmus and strabismus [7].
Early motor, as well as intellectual, development is
delayed, with most patients starting to walk between 2
and 3 years and to talk after 3 years of age.
On physical examination, all patients are of small stature
and most are also of low weight. Head circumference is
reduced; however, its ratio to height is normal. Facial dys-
morphism develops in late childhood and is more evident
in male than in female subjects. It includes a prominent
midface with a well developed nose, thickening of the
perioral tissues, forwardly directed anterior dentition and
hypognathism. Skeletal deformities are present in most
patients, especially adults. Foot deformities, namely pes
cavus or pes equinovarus with clawing of the toes, are very
common. Claw hand deformity develops in the course of
the disease and is observed in most adult patients. Kypho-
scoliosis may develop and leads to reduced vital capacity.
The most striking neurological manifestation is a symmet-
ric, distally accentuated, predominantly motor peripheral
neuropathy. Motor involvement is evident in all affected
subjects, including young children, and progresses to
severe disability in the third decade. Loss or depression of
tendon reflexes, initially in the lower limbs, is universally
observed. Nerve conduction velocity is normal in early
infancy and declines after age 18 months, stabilizing at
~20 m/s after 4 years [8]. Distal motor latency is increased.
Sensory action potential values are of normal amplitude,
suggesting a relatively uniform degree of slowing of con-
duction across nerve fibres, consistent with congenital
hypomyelination. Neuropathological evidence of primary
hypomyelination is provided by nerve biopsy studies,
showing also a superimposed demyelination/remyelina-
tion and axonal degeneration increasing with age.
Other, less consistent, neurological abnormalities include
bilaterally extensor plantar responses, choreiform move-
ments, mild ataxia and upper limb postural tremor.
Abnormal electroencephalographic recordings are a very
common finding, with usually diffuse slow wave activity.
Brain and spinal cord abnormalities have been identified
in many patients by magnetic resonance imaging (MRI)
examination [2]. The changes appear to be age-related and
may not be detectable in affected children. The abnormal-
ities include diffuse cerebral atrophy with enlargement of
the lateral ventricles, and spinal cord atrophy sometimes
also involving the medulla oblongata. A recent study,
using diffusion tensor MRI in a small group of CCFDN
patients revealed a higher apparent diffusion coefficient
and lower fractional anisotropy in the vermis and medulla
oblongata, suggesting axonal loss in these parts of the
brain [8]. Mild non-progressive cognitive deficit is often
present; however, its assessment should take into account
the visual impairment, as well as possible social depriva-
tion of the affected subjects.
Severe myalgia, weakness and massive myoglobinuria,
presumably following unspecified viral infections, are
reported in an increasing number of patients. Para-infec-
tious rhabdomyolysis, which is rare in the general popu-
lation [9], may be a common environmentally-triggered
feature of the CCFDN syndrome, possibly related to anPage 2 of 5
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demands imposed by the febrile condition. Patients and
care-providers should be aware of this complication and
seek prompt medical attention to prevent acute kidney
failure.
Sex hormone (testosterone and oestrogen) levels are
decreased. External secondary sexual characteristics
appear normal; however most adult female patients have
irregular menstrual cycles progressing to secondary amen-
orrhea at age 25–35 years. Bone mineral density is
reduced both in compact and trabecular bone.
Aetiology
CCFDN is a genetically homogeneous condition, where
all patients are homozygous for the same ancestral muta-
tion. The CCFDN gene maps to 18qter [1]. The recently
identified mutation is a C>T substitution 389 bp down-
stream of the exon 6/intron 6 junction of the Carboxy-Ter-
minal Domain Phosphatase 1 (CTDP1) gene [3]. The
mutation occurs in an antisense Alu element and triggers
a rare mechanism of aberrant splicing: it creates a perfect
donor splice site which, in turn, activates an upstream
cryptic acceptor site, leading to the insertion of 95 nucle-
otides of the intronic Alu sequence into the processed
CTDP1 transcript. The insertion causes a shift in the read-
ing frame and a premature termination codon. Since both
normal and aberrant splicing occur in CCFDN cells [3],
the mutation is predicted to lead to partial protein defi-
ciency. The CTDP1 gene encodes a protein phosphatase,
commonly referred to as FCP1, whose only known sub-
strate is the phosphorylated serine residues of the carboxy-
terminal domain (CTD) of the largest subunit of RNA
polymerase II [10]. RNA polymerase II is responsible for
the transcription of protein-encoding genes in eukaryotic
cells, and the level of CTD phosphorylation is considered
to be a key mechanism for the regulation of gene expres-
sion [11]. In addition to, and independent of its enzyme
activity, FCP1 has been proposed to play other roles in
transcription: as a positive transcription regulator, an
elongation factor, a factor counteracting the Srb-10 com-
plex (which down-regulates the expression of cell cycle
and developmentally regulated genes), and in the mecha-
nisms of splicing. At this stage, it is unclear which molec-
ular function(s) is most affected by the CCFDN mutation
and thus responsible for the disease phenotype.
Regardless of the need for understanding the specific
molecular pathogenesis, it is already clear that CCFDN
affects basic cellular mechanisms of gene expression and
their developmental regulation. The disorder belongs to
the (currently) small group of "transcription syndromes"
and, at present, is the only known defect directly involving
RNA polymerase II-mediated gene expression.
Diagnostic methods
The clinical diagnosis is based on observation of the
symptoms and manifestations described above, sup-
ported by electrophysiological and brain imaging studies.
The definitive diagnosis is molecular, based on homozy-
gosity for the splicing mutation in intron 6 of the CTDP1
gene. The test is a polymerase chain reaction (PCR)-based
restriction fragment length polymorphism (RFLP) assay,
relying on the abolition of an NlaIII restriction site by the
mutation [3]. Molecular testing based on linkage analysis
may be problematic, due to the recent origin of the muta-
tion on a common haplotype background and the persist-
ing presence of the ancestral haplotype on normal
chromosomes in the same population [3].
So far, CCFDN is known to affect patients of Roma
(Gypsy) ethnicity, with the history of this population
helping to identify the molecular basis of the disease. It is
logical to expect that there are affected individuals of dif-
ferent ethnicity displaying similar phenotypic features
and that these patients would have other mutations of the
same gene. In such cases, sequencing analysis of CTDP1,
as well as of the SIL1 gene recently found to be mutated in
Marinesco-Sjögren syndrome (MSS) [12,13], will not only
help the diagnostic investigations in the specific affected
families, but will also contribute to understanding the
molecular pathogenesis of the two disorders. It is advisa-
ble to make cultured cells (skin fibroblasts, lymphoblast-
oid cells, myoblasts, or Schwann cells) available for
molecular studies, since the mutation(s) can be predicted
to cause partial deficiency, and are thus likely to occur in
introns and regulatory sequences and to require RNA-
based analysis for elucidation.
Differential diagnosis
In early infancy, when most features of the CCFDN syn-
drome have yet to appear, a differential diagnosis to be
considered is galactokinase deficiency, an inborn error of
metabolism common among the Roma which, if
untreated, leads to the development of cataracts in the
first weeks of life [14,15]. The two conditions can be dis-
tinguished by specialised ophthalmological examination,
searching for the additional ocular manifestations of
CCFDN (described above), as well as by testing for the
two founder mutations – in the CTDP1 and GALK1 genes.
The major differential diagnosis is MSS [12,13,16,17],
whose phenotypic features partly overlap those of CCFDN
[6,8] (Table 1). While substantial clinical heterogeneity
exists among patients diagnostically labelled as MSS,
mutations in the SIL1 gene on chromosome 5q seem to
result in a relatively homogeneous phenotype, character-
ised by congenital cataracts, developmental delay, severe
ataxia and cerebellar atrophy, and chronic myopathy
[12,13]. The heterogeneity is still incompletely resolved,Page 3 of 5
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to show linkage to 5q and/or mutations in SIL1 [13,18].
Genetic counselling
The disorder is autosomal recessive, with a Mendelian risk
of 25% for subsequent pregnancies. Given the high fre-
quency of the mutation, and the endogamous tradition of
the affected population, discussions of consanguinity are
irrelevant and can be counterproductive. Most affected
families are very receptive to genetic counselling and pre-
dictive testing.
Prenatal diagnosis
Prenatal analysis is best performed by testing for the dis-
ease mutation on DNA extracted from chorionic villus
samples.
Management
Management includes the treatment of cataracts, and
rehabilitation and corrective surgery for the peripheral
neuropathy. Eye surgery may be complicated by strong
postoperative inflammatory reactions, as well as a strong
unspecific foreign-body reaction to contact lenses and
intra-ocular lenses, with a generally better tolerance to
intra-ocular lenses [7]. CCFDN patients are prone to
developing severe and potentially life-threatening compli-
cations during anaesthesia, such as pulmonary oedema,
inspiratory stridor, malignant hyperthermia and epileptic
seizures [6,7] and thus need close monitoring and possi-
bly intensive post-operative care.
Prognosis
The recent recognition of CCFDN as a novel disease
entity, and the lack of prospective follow-up does not
allow an evidence-based prognosis regarding life expect-
ancy. Current observations indicate that patients survive
well into adulthood (the oldest known cases being over
40 years of age). While the most disabling manifestations
involving the eyes and the peripheral nervous system are
not curable, they are manageable, allowing an acceptable
quality of life and performance of daily activities.
Unresolved questions
Clinical features
The nature of the pathological changes in the central nerv-
ous system is still to be resolved. At present, it is unclear
whether the brain and spinal cord atrophy observed on
MRI result from primary hypomyelination, as is the case
for the peripheral nervous system [2,5] or secondary
degenerative processes. Furthermore, the recently
reported diffusion tensor MRI evidence of axonal loss in
the brain [8] needs to be confirmed in larger groups of
patients. The nature of the endocrine abnormalities is also
poorly defined. Although the hypogonadism seen in
CCFDN patients has been classified as hypogonado-
trophic [2], the evidence is not conclusive, and the prob-
lem may in fact reside in changes in the expression profile
of the gonads. The frequency of rhabdomyolysis in
CCFDN patients and the nature of the factors triggering
this severe complication remain to be determined; careful
collection of case histories and patient follow-up will pro-
vide this information.
Molecular mechanisms
Further studies are needed to elucidate the specific molec-
ular processes that lead to the phenotypic manifestations
of CCFDN. The mutated protein is believed to be of uni-
versal importance for the regulation of RNA polymerase II
activity and the CCFDN mutation is expressed in all cell
types investigated, yet the clinical phenotype is limited to
just a few of them. This cell specificity, possibly resulting
from differences in back-up mechanisms and in the rela-
tive contribution of other CTD phosphatases to RNA
polymerase II regulation, is a major question, resolution
Table 1: Clinical criteria in differential diagnosis of Congenital Cataracts Facial Dysmorphism Neuropathy (CCFDN) and Marinesco-
Sjögren syndrome (MSS)
SYMPTOMS CCFDN MSS
Microcornea, microphthalmos, micropupils Yes No
Developmental delay Yes Yes
Small stature Yes Yes
Facial dysmorphism Yes, mild, late childhood No
Peripheral neuropathy Yes, hypomyelinating Rare, variable type
Ataxia Rare, mild* Severe cerebellar
Brain MRI Cerebral atrophy* Cerebellar atrophy
Myopathy Acute para-infectious rhabdomyolysis* Chronic
Cognitive deficit Mild* Variable degree
Hypogonadism Mild* Variable in degree and origin (hypo/hypergonadotrophic)
* Manifestations whose frequency and nature require further characterisation.Page 4 of 5
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of which will not only help understanding of the disease
itself, but could also contribute to unravelling fundamen-
tal mechanisms of the regulation of gene expression.
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